Royal Bank Of Canada Forecasts Strong Price Appreciation for Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International (NYSE:CRL) had its price target boosted by equities researchers at Royal Bank Of Canada from $282.00 to $322.00 in a research report issued on Friday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Royal Bank Of Canada’s target price indicates a potential upside of 10.64% from the company’s current price.

Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. raised Charles River Laboratories International from a “neutral” rating to an “overweight” rating and upped their target price for the company from $180.00 to $310.00 in a research report on Thursday, August 6th. Citigroup reissued a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Argus set a $330.00 price target on shares of Charles River Laboratories International in a report on Thursday, September 17th. BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Finally, Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a report on Monday, August 10th. Eleven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International currently has an average rating of “Moderate Buy” and an average price target of $282.81.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $291.03 on Friday. The firm has a 50-day moving average of $269.08 and a two-hundred day moving average of $212.48. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The stock has a market cap of $13.89 billion, a P/E ratio of -59.72, a PEG ratio of 2.80 and a beta of 1.40. Charles River Laboratories International has a 1-year low of $145.32 and a 1-year high of $303.30.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the previous year, the company earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, research analysts expect that Charles River Laboratories International will post 11.33 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Victoria Creamer sold 4,179 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the transaction, the executive vice president directly owned 30,051 shares of the company’s stock, valued at approximately $7,788,017.16. This represents a 12.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Shannon M. Parisotto sold 2,039 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $294.12, for a total value of $599,710.68. Following the transaction, the executive vice president owned 4,807 shares of the company’s stock, valued at approximately $1,413,834.84. The trade was a 29.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 165,990 shares of company stock worth $42,606,388. 1.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CRL. Dimensional Fund Advisors LP boosted its position in shares of Charles River Laboratories International by 14.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after buying an additional 210,260 shares during the period. Geode Capital Management LLC grew its stake in shares of Charles River Laboratories International by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock worth $254,186,000 after purchasing an additional 9,756 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Charles River Laboratories International by 5.0% during the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock valued at $195,792,000 after purchasing an additional 54,500 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in shares of Charles River Laboratories International by 8.7% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 836,240 shares of the medical research company’s stock valued at $166,813,000 after purchasing an additional 66,803 shares during the period. Finally, Amundi raised its stake in shares of Charles River Laboratories International by 175.2% during the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after purchasing an additional 492,301 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

More Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Charles River reaffirmed its fiscal 2026 revenue outlook of approximately $3.9 billion and raised its EPS guidance to $11.45, modestly above the analyst consensus of $11.33. Charles River sets 2030 targets, lifts 2026 earnings outlook
• Positive Sentiment: At Investor Day, management outlined 2030 growth objectives that imply stronger revenue and earnings expansion over the long term. The targets, together with the reaffirmed 2026 outlook, prompted a sharp rise in the stock as investors responded favorably to the company’s strategy and earnings potential. Charles River Stock Rises After Unveiling 2030 Growth Targets
• Positive Sentiment: Robert W. Baird raised its price target from $291 to $334 and maintained an “outperform” rating, citing additional upside following the Investor Day update. Baird price-target update
• Neutral Sentiment: Mizuho increased its price target from $264 to $295 but retained a “neutral” rating. The limited implied upside suggests the firm views much of the favorable Investor Day news as already reflected in CRL’s elevated share price. Mizuho price-target update
• Negative Sentiment: A Seeking Alpha analysis argued that the positive Investor Day announcements are “fully priced in,” raising concerns that the stock’s valuation leaves less room for further gains unless Charles River delivers on its long-term targets. Positive Investor Day Is Fully Priced In

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.